PT2146961E - Derivados de n-óxido e/ou di-n-óxido de estabilizadores / moduladores dos recetores da dopamina exibindo perfis de efeitos secundários cardiovasculares melhorados - Google Patents
Derivados de n-óxido e/ou di-n-óxido de estabilizadores / moduladores dos recetores da dopamina exibindo perfis de efeitos secundários cardiovasculares melhorados Download PDFInfo
- Publication number
- PT2146961E PT2146961E PT08741904T PT08741904T PT2146961E PT 2146961 E PT2146961 E PT 2146961E PT 08741904 T PT08741904 T PT 08741904T PT 08741904 T PT08741904 T PT 08741904T PT 2146961 E PT2146961 E PT 2146961E
- Authority
- PT
- Portugal
- Prior art keywords
- oxide
- dopamine receptor
- cardiovascular side
- improved cardiovascular
- displaying improved
- Prior art date
Links
- 102000015554 Dopamine receptor Human genes 0.000 title 1
- 108050004812 Dopamine receptor Proteins 0.000 title 1
- 150000001204 N-oxides Chemical class 0.000 title 1
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical class NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 title 1
- 230000002526 effect on cardiovascular system Effects 0.000 title 1
- 230000000694 effects Effects 0.000 title 1
- 239000003381 stabilizer Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
- C07D211/94—Oxygen atom, e.g. piperidine N-oxide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Virology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Anesthesiology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0700893 | 2007-04-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT2146961E true PT2146961E (pt) | 2014-04-30 |
Family
ID=39864178
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT08741904T PT2146961E (pt) | 2007-04-12 | 2008-04-11 | Derivados de n-óxido e/ou di-n-óxido de estabilizadores / moduladores dos recetores da dopamina exibindo perfis de efeitos secundários cardiovasculares melhorados |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US9139525B2 (enExample) |
| EP (1) | EP2146961B1 (enExample) |
| JP (1) | JP5393654B2 (enExample) |
| CN (1) | CN101711236B (enExample) |
| AU (1) | AU2008239841B2 (enExample) |
| BR (1) | BRPI0810161A2 (enExample) |
| CA (1) | CA2683719C (enExample) |
| CY (1) | CY1115337T1 (enExample) |
| DK (1) | DK2146961T3 (enExample) |
| ES (1) | ES2458592T3 (enExample) |
| HR (1) | HRP20140380T1 (enExample) |
| IL (1) | IL201401A (enExample) |
| MX (1) | MX2009011020A (enExample) |
| NZ (1) | NZ580856A (enExample) |
| PL (1) | PL2146961T3 (enExample) |
| PT (1) | PT2146961E (enExample) |
| RU (1) | RU2470013C2 (enExample) |
| SI (1) | SI2146961T1 (enExample) |
| WO (1) | WO2008127188A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE46117E1 (en) | 1999-12-22 | 2016-08-23 | Teva Pharmaceuticals International Gmbh | Modulators of dopamine neurotransmission |
| JP5716202B2 (ja) | 2008-11-24 | 2015-05-13 | インテグレイティブ・リサーチ・ラボラトリーズ・スウェーデン・アーベー | 皮質のカテコールアミン作動性神経伝達のモジュレーターとしての３−フェニル−３−メトキシピロリジン誘導体 |
| WO2011107583A1 (en) | 2010-03-04 | 2011-09-09 | Nsab, Filial Af Neurosearch Sweden Ab, Sverige | Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders |
| WO2012028635A1 (en) | 2010-09-03 | 2012-03-08 | Nsab, Filial Af Neurosearch Sweden Ab, Sverige | Deuterated analogs of pridopidine useful as dopaminergic stabilizers |
| US9018202B2 (en) * | 2010-12-03 | 2015-04-28 | Allergan, Inc. | Methods for treating diseases of the retina |
| CN103958469B (zh) | 2011-09-07 | 2016-04-20 | 梯瓦制药国际有限责任公司 | 一种新的普利多匹定盐酸盐多晶型形态 |
| MX347209B (es) | 2011-12-08 | 2017-04-19 | Teva Pharmaceuticals Int Gmbh | La sal de bromhidrato de pridopidina. |
| AU2013243461A1 (en) | 2012-04-04 | 2014-11-06 | Teva Pharmaceuticals International Gmbh | Pharmaceutical compositions for combination therapy |
| US11090297B2 (en) | 2013-06-21 | 2021-08-17 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating huntington's disease |
| DK3010506T3 (da) | 2013-06-21 | 2021-07-12 | Prilenia Neurotherapeutics Ltd | Pridopidin i behandling af huntingtons sygdom |
| TW201613859A (en) * | 2014-06-30 | 2016-04-16 | Teva Pharma | Analogs of PRIDOPIDINE, their preparation and use |
| CA2970799A1 (en) | 2014-12-22 | 2016-06-30 | Teva Pharmaceuticals International Gmbh | L-tartrate salt of pridopidine |
| US10603311B2 (en) | 2015-02-25 | 2020-03-31 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine to improve cognitive function and for treating Alzheimer's disease |
| US11471449B2 (en) | 2015-02-25 | 2022-10-18 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine to improve cognitive function and for treating Alzheimer's disease |
| AR105434A1 (es) | 2015-07-22 | 2017-10-04 | Teva Pharmaceuticals Int Gmbh | Proceso para preparar pridopidina |
| JP7034488B2 (ja) | 2016-02-24 | 2022-03-14 | プリレニア・ニューロセラピューティクス・エルティーディー | プリドピジンを使用する神経変性眼疾患の治療 |
| CN110012661A (zh) | 2016-08-24 | 2019-07-12 | 普瑞尼亚医疗发展有限公司 | 普利多匹定用于治疗肌张力障碍的用途 |
| DK3504187T3 (da) | 2016-08-24 | 2025-04-14 | Prilenia Neurotherapeutics Ltd | Anvendelse af pridopidin til behandling af funktionel tilbagegang |
| US12102627B2 (en) | 2016-09-16 | 2024-10-01 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine for treating rett syndrome |
| BR112019015000A2 (pt) | 2017-01-20 | 2020-04-07 | Prilenia Neurotherapeutics Ltd. | uso de pridopidina para o tratamento da síndrome do x frágil |
| AU2018317346B2 (en) | 2017-08-14 | 2021-08-26 | Prilenia Neurotherapeutics Ltd. | Method of treating amyotrophic lateral sclerosis with pridopidine |
| CN111278431A (zh) | 2017-08-30 | 2020-06-12 | 普瑞尼亚神经治疗有限公司 | 普利多匹定的高浓度剂型 |
| US12036213B2 (en) | 2017-09-08 | 2024-07-16 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating drug induced dyskinesias |
| JP2020533296A (ja) | 2017-09-08 | 2020-11-19 | プリレニア ニューロセラピューティクス リミテッド | 薬物誘発性ジスキネジアを治療するためのプリドピジン |
| AU2020218158B2 (en) | 2019-02-04 | 2023-08-03 | Prilenia Neurotherapeutics Ltd. | Low dose pridopidine for Parkinson's Disease and other diseases associated with parkinsonism |
| CN116472043A (zh) * | 2020-10-20 | 2023-07-21 | 普瑞尼亚神经治疗有限公司 | 普利多匹定和类似物用于治疗焦虑和抑郁的用途 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1217296A (en) | 1917-01-11 | 1917-02-27 | Lewis A Peckham | Shock-absorber. |
| US2813098A (en) | 1955-08-16 | 1957-11-12 | Upjohn Co | 3-methoxy-n-methylmorphinan n-oxide |
| US2813097A (en) | 1955-08-16 | 1957-11-12 | Upjohn Co | 3-hydroxy-n-methylmorphinan-n-oxide |
| US3131185A (en) | 1959-03-18 | 1964-04-28 | Orsymonde | Nicotinic esters of hydroxyl derivatives of the phenanthrenic alkaloids of opium, and process for the preparation of these esters |
| BE638369A (enExample) | 1962-10-10 | |||
| CH481123A (de) | 1966-09-21 | 1969-11-15 | Geigy Ag J R | Verfahren zur Herstellung von neuen, kondensierten heterocyclischen Verbindungen |
| AU658134B2 (en) | 1989-12-28 | 1995-04-06 | Virginia Commonwealth University | Sigma receptor ligands and the use thereof |
| ATE201669T1 (de) * | 1991-04-17 | 2001-06-15 | Upjohn Co | Substituierte (s)-3-phenylpiperidin derivate, deren herstellung und deren verwendung als dopamin autorezeptor antagonisten |
| JPH06509069A (ja) | 1991-06-27 | 1994-10-13 | バージニア・コモンウェルス・ユニバーシティ | シグマレセプターリガンドおよびその用途 |
| IL112099A (en) * | 1993-12-23 | 1999-07-14 | Ortho Pharma Corp | N-oxides of 4-arylpiperazines and 4-arylpiperidines and pharmaceutical compositions containing them |
| CA2144669A1 (en) | 1994-03-29 | 1995-09-30 | Kozo Akasaka | Biphenyl derivatives |
| DE69912635T2 (de) | 1998-11-23 | 2004-05-13 | Sepracor Inc., Marlborough | Olanzapin-n-oxide enthaltende pharmaceutische zusammensetzungen |
| SE9904724D0 (sv) * | 1999-12-22 | 1999-12-22 | Carlsson A Research Ab | New modulators of dopamine neurotransmission I |
| SE9904723D0 (sv) * | 1999-12-22 | 1999-12-22 | Carlsson A Research Ab | New modulators of dopamine neurotransmission II |
| SE0200301D0 (sv) * | 2002-02-01 | 2002-02-01 | Axon Biochemicals Bv | Thio-carbostyril derivative |
| NZ552411A (en) | 2004-06-08 | 2010-04-30 | Nsab Af Neurosearch Sweden Ab | New disubstituted phenylpiperidines/piperazines as modulators of dopamine neurotransmission |
| MXPA06013941A (es) | 2004-06-08 | 2007-12-10 | Neurosearch Sweden Ab | Fenilpiperidinas disustituidas, novedosas, como moduladores de la neurotransmision de dopamina y serotonina. |
| JP2008509909A (ja) * | 2004-08-11 | 2008-04-03 | ウィリアムスバーグ・ホールディングス・エルエルシー | 心毒性のない医薬化合物 |
| PL1802573T3 (pl) | 2004-10-13 | 2017-03-31 | Teva Pharmaceuticals International Gmbh | Proces syntezy 4-(3-metanosulfonylofenylo)-1-N-propylopiperydyny |
| ATE417834T1 (de) * | 2005-08-22 | 2009-01-15 | Solvay Pharm Bv | N-oxide als prodrugs von piperazin- und piperidinderivaten |
| SE529246C2 (sv) | 2005-10-13 | 2007-06-12 | Neurosearch Sweden Ab | Nya disubstituerade fenyl-piperidiner som modulatorer för dopaminneurotransmission |
| AU2007247251B2 (en) | 2006-05-02 | 2011-11-03 | Solvay Pharmaceuticals B.V. | N-oxides of pyridylmethylpiperazine and -piperidine derivatives |
| WO2011107583A1 (en) * | 2010-03-04 | 2011-09-09 | Nsab, Filial Af Neurosearch Sweden Ab, Sverige | Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders |
| US20130203886A1 (en) * | 2010-03-05 | 2013-08-08 | Nileshkumar Prakash Kukalyekar | Process for the production of an uhmwpe article |
| WO2012028635A1 (en) | 2010-09-03 | 2012-03-08 | Nsab, Filial Af Neurosearch Sweden Ab, Sverige | Deuterated analogs of pridopidine useful as dopaminergic stabilizers |
| CN103958469B (zh) | 2011-09-07 | 2016-04-20 | 梯瓦制药国际有限责任公司 | 一种新的普利多匹定盐酸盐多晶型形态 |
| MX347209B (es) | 2011-12-08 | 2017-04-19 | Teva Pharmaceuticals Int Gmbh | La sal de bromhidrato de pridopidina. |
| AU2013243461A1 (en) | 2012-04-04 | 2014-11-06 | Teva Pharmaceuticals International Gmbh | Pharmaceutical compositions for combination therapy |
| WO2014052933A1 (en) | 2012-09-27 | 2014-04-03 | Teva Pharmaceutical Industries Ltd. | Laquinimod and pridopidine for treating neurodegenerative disorders |
| US20140088145A1 (en) | 2012-09-27 | 2014-03-27 | Teva Pharmaceutical Industries, Ltd. | Combination of rasagiline and pridopidine for treating neurodegenerative disorders, in particular huntington's disease |
-
2008
- 2008-04-11 CN CN2008800175988A patent/CN101711236B/zh not_active Expired - Fee Related
- 2008-04-11 DK DK08741904T patent/DK2146961T3/da active
- 2008-04-11 WO PCT/SE2008/050414 patent/WO2008127188A1/en not_active Ceased
- 2008-04-11 RU RU2009141300/04A patent/RU2470013C2/ru not_active IP Right Cessation
- 2008-04-11 PT PT08741904T patent/PT2146961E/pt unknown
- 2008-04-11 AU AU2008239841A patent/AU2008239841B2/en not_active Ceased
- 2008-04-11 EP EP20080741904 patent/EP2146961B1/en not_active Not-in-force
- 2008-04-11 SI SI200831188T patent/SI2146961T1/sl unknown
- 2008-04-11 ES ES08741904T patent/ES2458592T3/es active Active
- 2008-04-11 HR HRP20140380AT patent/HRP20140380T1/hr unknown
- 2008-04-11 US US12/595,472 patent/US9139525B2/en active Active
- 2008-04-11 PL PL08741904T patent/PL2146961T3/pl unknown
- 2008-04-11 BR BRPI0810161 patent/BRPI0810161A2/pt not_active IP Right Cessation
- 2008-04-11 MX MX2009011020A patent/MX2009011020A/es unknown
- 2008-04-11 JP JP2010502976A patent/JP5393654B2/ja not_active Expired - Fee Related
- 2008-04-11 CA CA2683719A patent/CA2683719C/en not_active Expired - Fee Related
- 2008-04-11 NZ NZ580856A patent/NZ580856A/en unknown
-
2009
- 2009-10-11 IL IL201401A patent/IL201401A/en not_active IP Right Cessation
-
2014
- 2014-04-25 CY CY20141100304T patent/CY1115337T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DK2146961T3 (da) | 2014-04-28 |
| ES2458592T3 (es) | 2014-05-06 |
| US9139525B2 (en) | 2015-09-22 |
| AU2008239841A1 (en) | 2008-10-23 |
| JP2010523651A (ja) | 2010-07-15 |
| WO2008127188A1 (en) | 2008-10-23 |
| RU2009141300A (ru) | 2011-05-20 |
| MX2009011020A (es) | 2009-10-30 |
| PL2146961T3 (pl) | 2014-09-30 |
| CN101711236A (zh) | 2010-05-19 |
| US20100105736A1 (en) | 2010-04-29 |
| NZ580856A (en) | 2011-11-25 |
| CA2683719A1 (en) | 2008-10-23 |
| SI2146961T1 (sl) | 2014-08-29 |
| HRP20140380T1 (hr) | 2014-08-15 |
| BRPI0810161A2 (pt) | 2014-12-30 |
| CA2683719C (en) | 2015-07-14 |
| AU2008239841B2 (en) | 2013-07-18 |
| EP2146961A4 (en) | 2011-08-03 |
| EP2146961B1 (en) | 2014-01-29 |
| RU2470013C2 (ru) | 2012-12-20 |
| JP5393654B2 (ja) | 2014-01-22 |
| IL201401A (en) | 2015-10-29 |
| CN101711236B (zh) | 2012-10-31 |
| IL201401A0 (en) | 2010-05-31 |
| EP2146961A1 (en) | 2010-01-27 |
| CY1115337T1 (el) | 2017-01-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL201401A0 (en) | N - oxide and/or di-n-oxide derivatives of dopamine receptor stabilizers/modulators displaying improved cardiovascular side-effects profiles | |
| IL201202A0 (en) | Imidazolidine carboxamide derivatives as p2x7 modulators | |
| IL205176A0 (en) | Pyridazinone derivatives and use thereof as p2x7 receptor inhibitors | |
| IL210412A0 (en) | Heterocyclic derivatives and uses thereof | |
| EP2265731A4 (en) | METHODS AND COMPOSITION FOR EVALUATING MEDICATION RESPONSE | |
| ZA201008611B (en) | Isoxazole derivatives and their use as metabotropic glutamate receptor potentiators | |
| EP2188295A4 (en) | PYRIDINE DERIVATIVES AND METHODS OF USE | |
| IL211042A0 (en) | Imidazopyridin-2-one derivatives and uses thereof | |
| IL206276A0 (en) | Pyridine derivatives | |
| ZA201103635B (en) | Azaquinolinone derivatives and uses thereof | |
| ZA201004914B (en) | Compositions and methods of detecting tiabs | |
| PL2615085T3 (pl) | Pochodne pirydynowe jako modulatory CFTR | |
| ZA201006475B (en) | Heterocyclic derivatives | |
| PL2110502T3 (pl) | Zawias puszkowy | |
| IL212070A (en) | Phenyl and pyridyl history of 7-piperidinoalkyl-4,3-dihydroquinolone | |
| BRPI0919331A2 (pt) | derivados de pirazolo piridina, composições farmacêuticas e métodos associados | |
| IL213570A (en) | History 8 - Alkoxy - s - Triazolo [5,1 - a] pyridine and pharmaceutical preparations containing them | |
| IL213346A0 (en) | Dihydropyridone amides as p2x7 modulators | |
| EP2081950A4 (en) | EXPRESSION PROFILES ASSOCIATED WITH IRINOTECAN TREATMENT | |
| EP2139891A4 (en) | 4-SUBSTITUTED AZAADAMANTANE DERIVATIVES AND METHODS OF USE | |
| IL213417A0 (en) | Dihydropyridone amides as p2x7 modulators | |
| ZA200809112B (en) | N-oxides of pyridylmethylpiperazine and -piperidine derivatives | |
| IL206951A0 (en) | 3-alkyl-piperazine derivatives and uses thereof | |
| ZA201100805B (en) | Derivatives of oxabispidine as neuronal nicotinic acetylcholine receptor ligands | |
| ZA200906572B (en) | Imidazolidine carboxamide derivatives as P2X7 modulators |